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Body fat estimates from bioelectrical
impedance equations in cardiovascular
risk assessment: The PREVEND
cohort study
Oyuntugs Byambasukh1,2, Michele F Eisenga3,
Ron T Gansevoort3, Stephan JL Bakker3 and Eva Corpeleijn1
Abstract
Aims: To investigate prospectively the association of body fat percentage (BF%) estimates using various equations from
bioelectrical impedance analysis (BIA) with cardiovascular events, compared with body mass index (BMI) and waist
circumference.
Methods and results: We used data of 34 BIA-BF%-equations that were used for estimation of BF% in 6486
(men¼ 3194, women¼ 3294) subjects. During a median follow-up of 8.3 years, 510 (7.9%) cardiovascular events (363
in men; 147 in women) occurred. In men, the crude hazard ratio (95% confidence interval) for BF% from the best
predicting BIA-BF%-equation was 3.97 (3.30–4.78) against 2.13 (1.85–2.45) for BF% from the BIA device’s BIA-BF%-
equation, 1.34 (1.20–1.49) for BMI and 1.49 (1.40–1.73) for waist circumference per log-1-SD increase of all. In women,
the hazard ratios for best predicting BIA-BF%-equation, BIA device estimation, BMI and waist circumference were 3.80
(2.85–4.99), 1.89 (1.57–2.28), 1.35 (1.21–1.51) and 1.52 (1.31–1.75), respectively. After adjustments for age, Framingham
cardiovascular disease risk score and creatinine excretion – a marker of muscle mass – BF%s and BMI remained inde-
pendently associated with cardiovascular events in both men and women, while waist circumference was independently
associated with cardiovascular events in men, but not in women. According to discrimination ability (C-index) and
additive predictive value (net reclassification index and integrated discrimination index) on obesity measures to the
Framingham cardiovascular disease risk score, BF% was superior to BMI and waist circumference in both men and
women.
Conclusions: BF% was independently associated with future cardiovascular events. Body fat estimates from the best-
predicting BIA-BF%-equations can be a more predictive measurement in cardiovascular risk assessment than BMI or
waist circumference.
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Introduction
Cardiovascular disease (CVD) is a major cause of mor-
tality in both men and women.1 While men have the
highest CVD incidence, CVD is increasing in women,
especially younger women.2 This creates a need to
investigate whether CVD indicators in women diﬀer
from those in men. One potential candidate could be
the risk related to adiposity.3 Although excess body fat
is recognized as an important causal factor, the strength
of its association with CVD may depend on the method
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used to measure adiposity, and there may be diﬀerences
between men and women.4,5
The most commonly used measures in CVD risk
assessment to date are body mass index (BMI) and
waist circumference.6 Importantly, these biometric
measures do not diﬀerentiate between fat and fat-free
mass, the latter of which includes muscle mass, which
may be inversely associated with CVD risk.7,8
Furthermore, the accurate evaluation of waist circum-
ference could depend on measurement procedures, and
it is also only a poor measure of the intra-abdominal fat
mass it is supposed to measure, thereby weakening its
association.9 Other methods used to measure adiposity
more accurately, such as magnetic resonance imaging,
dual-energy X-ray absorptiometry or computed tomog-
raphy scan, are usually expensive, labour-intensive and
require radiation exposure.10,11 The exception may be
bioelectrical impedance analysis (BIA). BIA is non-
invasive, feasible, low cost and potentially useful,
particularly in clinical evaluation.11,12 The principle
underpinning this method is that measurement is pos-
sible because lean body mass conducts electricity more
eﬃciently than fat mass does. By placing electrodes on
the hands and feet, for example, it is possible quickly to
measure how eﬃciently electricity is conducted through
the body or impeded.10,12 Several BIA-body fat per-
centage (BF%)-equations are available which use
impedance measures to calculate body fat, fat-free
mass and total body water.10,12,13
Previous studies have compared how various obesity
measures are associated with individuals’ cardiovascu-
lar risk proﬁles. Few have included BIA, and it is not
clear which measure best predicts CVD.5,13–15 Another
issue is that, with the plethora of BIA-BF%-equations
available for estimating BF%, it is not clear which
equation is best.13 Therefore, we hypothesized that
BF% estimated by the best ﬁtted BIA-BF%-equation
might be a better predictor of future cardiovascular
events than BMI and waist circumference.
The aim of this study is to investigate prospectively
the association between estimated body fat measured
by bioelectrical impedance analysis with future cardio-
vascular events, compared with BMI and waist circum-
ference, and particularly to assess the predictive value
of body fat estimates using various BIA-BF%-equa-




This study was conducted with participants from the
Prevention of Renal and Vascular End-stage Disease
(PREVEND) study. The PREVEND is a prospective
Dutch cohort drawn from the general population,
which began in 1997. The study design and recruitment
processes are described in detail elsewhere.16 We used
data from the second survey (2001–2002, n¼ 6894) as
the baseline for the current analysis because the BIA
measurement was only available from this period. We
excluded participants with a history of CVD (n¼ 201)
and missing BIA data (n¼ 168). Moreover, 39 partici-
pants were lost to follow-up between the baseline and
the ﬁrst cardiovascular event, leaving a total of 6486
participants.
The PREVEND study was approved by the local
medical ethics committee of the University Medical
Centre Groningen and conducted in accordance with
the Declaration of Helsinki. All participants provided
informed written consent.16
Measurements at baseline
Body weight and height were measured to calculate
BMI as the ratio between weight (kilograms) and the
square of height (metres). Minimum waist circumfer-
ence was measured on bare skin at the natural inden-
tation between the 10th rib and the iliac crest. When
there was no indentation we measured it in the middle
between navel and rib cage. Systolic and diastolic blood
pressures were calculated as the mean of the last two
measurements.16 A single frequency BIA device (BIA
101, RJL systems, Akern SRL, Italy) was used to meas-
ure whole-body electrical impedance at 50 kHz between
the hand and the foot. The bioelectrical impedance
measures obtained were used to estimate body fat per-
centages.16 Creatinine excretion – a marker of muscle
mass – was calculated as the mean of the two 24-h urine
collections.8 The analytical methods for urine collection
and other fasting blood sample methods are described
in greater detail elsewhere.8,16
Baseline cardiovascular risk was evaluated using the
Framingham 10-year CVD risk score including age,
total and high-density lipoprotein (HDL) cholesterol
level, current smoking status, systolic blood pressure,
anti-hypertensive medication use and diabetes.17
Prevalent CVD was deﬁned based on self-reported
diagnosis by a physician of cardiac, cerebral and per-
ipheral vascular morbidity.
Body fat estimation
The device we used to measure bioelectrical impedance
provided an estimate of BF% using the manufacturer’s
unpublished BIA-BF%-equation. We also used 33
BIA-BF%-equations to estimate BF%s. The equations
were selected based on their having been developed
for adults (Supplementary Material Table S1
online).10,12,13,18
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BIA-BF%-equations are developed to estimate vari-
ous aspects of the body composition, including lean
body mass (LBM), fat-free mass (FFM), total body
water (TBW) and body fat mass. We used the following
conversions to estimate BF%: FFM¼ 0.97 * LBM for
men and FFM¼ 0.92 * LBM for women; FFM¼
TBW/0.73; BF%¼ (body weight – FFM)/body
weight.10,13 After conversion, a total of 34 diﬀerent
body fat estimates were eligible for evaluation for the
prediction of CVD.
Cardiovascular events
We used the combined incidence of cardiovascular
morbidity and cardiovascular mortality as our outcome
measure, which we term ‘cardiovascular event’ in the
remaining analyses. Information on cardiovascular
morbidity was obtained from PRISMANT, the Dutch
national registry of hospital discharge diagnoses.
Data on mortality were obtained from the municipal
register. Outcome data were coded according to the
International Classiﬁcation of Diseases, Ninth
Revision (ICD-9) until 1 January 2009 and after this
date ICD-10 codes were used. Cardiovascular events
were deﬁned as follows: acute myocardial infarction,
acute and subacute ischaemic heart disease, subarach-
noid haemorrhage, intracerebral haemorrhage, other
intracranial haemorrhage, occlusion or stenosis of the
pre-cerebral or cerebral arteries, coronary artery bypass
grafting or percutaneous transluminal coronary angio-
plasty, and other vascular interventions. Follow-up was
deﬁned in our study as the period from the second
survey to the date of the ﬁrst cardiovascular event,
death or 1 January 2011.
Statistical analysis
All the analyses were performed separately for men and
women. The study characteristics were expressed as
means with a standard deviation (SD) for normally
distributed variables, medians with interquartile range
for non-normally distributed variables or numbers with
percentages (%) according to the participants with and
without cardiovascular events. The diﬀerences between
groups were compared using Student’s t-test or the
Mann–Whitney U test and Chi-Square test. The age-
adjusted Pearson partial correlation coeﬃcient was cal-
culated to evaluate associations of body fat estimates
with baseline characteristics.
Cox proportional hazard regression analysis was
used to examine the association between BF% from
various BIA-BF%-equations and future cardiovascular
events and to compare this association with BMI and
waist circumference. After crude Cox regression ana-
lysis, we adjusted all the obesity measures for age
(Model1), Framingham CVD Risk Score (Model2)
and creatinine excretion – a marker of muscle mass –
(Model3). The outcomes were presented as hazard ratio
per standardized log (1-SD) unit increase, to enable
better comparison between the obesity measures. To
compare the hazard ratio for obesity measures,
the z-statistic test was calculated and each BIA-
BF%-equation was compared with the BMI and
waist circumference respectively.19 Product-terms of
obesity measures and gender were added to test for
potential gender diﬀerences of the associations of obes-
ity measures with CVD.
Harrell’s C-index was used to compare the discrim-
ination of the obesity measures by adding each obesity
measure (extended models) to the Framingham CVD
risk score (base model) for the CVD prediction17,20
based on regression analysis. In addition, signiﬁcance
of the increases in C-index was tested by diﬀerences in -
2 log likelihood of regression models with and without
obesity measures. Furthermore, the net reclassiﬁcation
index (NRI) and integrated discrimination index (IDI)
were used to assess the additive predictive value of
obesity measures over the Framingham CVD risk
score as the general CVD risk factor in assessing the
improvement of obesity measures.21 Calculations were
based on the movement of an individual ‘up’ or ‘down’
when reclassifying people with and without cardiovas-
cular events through the addition of each obesity meas-
ure to the Framingham CVD risk score (NRI) and on
the improvement in the mean sensitivity and any
increase in 1-Speciﬁty with obesity measures (IDI).21
Subgroup analysis was performed in age categories.
The population was categorized as being over or under
55 years old, according to the World Health
Organization guideline.22 The analysis was not per-
formed for the female population, as the number of
events was insuﬃcient.
Data used to calculate the Framingham CVD risk
score up to 3.0% was missing. We performed a single
imputation with predictive mean matching for missing
data. A two-sided statistical signiﬁcance was set at
p< 0.05 for all tests. All statistical analyses were per-
formed using SPSS software V.22 (Chicago, IL, USA)
and R software V.3.2.2 (http://www.r-project.org) and
its libraries ‘survIDINRI’ and ‘CsChange’.
Results
The male and female participants who experienced a
cardiovascular event were older and had worse cardio-
metabolic proﬁles with higher BMI but lower muscle
mass compared with participants who had not experi-
enced a cardiovascular event (Table 1). The BF% from
BIA device and other BF%s from BIA-BF%-equations
(Supplementary Table S2) were all signiﬁcantly higher
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in both male and female participants with a cardiovas-
cular event (p< 0.05). Age-adjusted Pearson correlation
analysis yielded body fat estimates from diﬀerent BIA-
BF%-equations which were all signiﬁcantly associated
with other obesity measures and creatinine excretion
(Supplementary Table S3) and CVD risk factors
(Supplementary Table S4).
A total of 510 (7.9%) participants experienced a car-
diovascular event (363 in men; 147 in women) after a
median follow-up of 8.3 (7.8–8.9) years. The hazard
ratio (95% conﬁdence interval) for the BF% from the
best predicting BIA-BF%-equation (Segal3) in men
was 3.97 (3.30–4.78), against 1.34 (1.20–1.49) for BMI
and 1.49 (1.40–1.73) for waist circumference.
Table 1. Baseline characteristics.
Total
CV event
Without With p value
Men
Number (%) 3194 (49.2) 2831 (47.7) 363 (71.2) –
Age, years 53.8 12.3 52.6 12.0 63.5 10.4 <0.0001
Obesity measures
Body fat mass, %a 26.9 6.3 26.5 6.2 30.1 5.8 <0.0001
BMI, kg/m2 26.7 3.7 26.6 3.7 27.7 3.5 <0.0001
Waist circumference, cm 97.0 11.1 96.5 11.0 101.3 10.6 <0.0001
Creatinine excretion, mmol/L) 14.88 3.27 14.98 3.27 14.16 3.18 <0.0001
Cardiovascular risk factors
Current smokers, n (%) 881 (27.6) 760 (26.8) 121 (33.3) 0.012
Alcohol drinkers, n (%) 2589 (81.1) 2319 (81.9) 270 (74.4) <0.0001
SBP, mmHg 129.2 16.8 129.2 16.8 141.6 20.1 <0.0001
Total cholesterol, mmol/L 5.41 1.03 5.40 1.01 5.52 1.17 0.033
HDL cholesterol, mmol/L 1.12 0.26 1.13 0.26 1.08 0.27 0.001
Triglycerides, mmol/L 1.52 1.19 1.48 1.13 1.80 1.54 <0.0001
C-reactive protein, mmol/L 1.27 (0.61–2.74) 1.18 (0.58–2.61) 2.04 (0.97–4.55) <0.0001
Framingham CVD risk score 13.9 5.8 13.3 5.7 17.1 3.7 <0.0001
Type 2 diabetes, n (%) 116 (3.6) 83 (2.9) 33 (9.1) <0.0001
Women
Number (%) 3292 (50.8) 3145 ( 52.6) 147 (28.8) –
Age, years 52.3 11.6 51.8 11.4 62.5 10.9 <0.0001
Obesity measures
Body fat mass, %a 36.3 7.3 36.1 7.3 40.2 6.5 <0.0001
BMI, kg/m2 26.6 4.9 26.5 4.9 28.6 5.2 <0.0001
Waist circumference, cm 87.3 12.5 87.1 12.4 93.0 12.3 <0.0001
Creatinine excretion, mmol/L 10.5 2.3 10.6 2.3 9.73 2.49 <0.0001
Cardiovascular risk factors
Current smokers, n (%) 933 (28.3) 880 (28.0) 53 (36.1) 0.040
Alcohol drinkers, n (%) 2207 (67.0) 2139 (68.0) 68 (46.3) <0.0001
SBP, mmHg 122.2 19.0 121.5 18.6 138.4 21.4 <0.0001
Total cholesterol, mmol/L 5.46 1.05 5.45 1.05 5.78 1.04 <0.0001
HDL cholesterol, mmol/L 1.37 0.32 1.38 0.32 1.27 0.32 <0.0001
Triglycerides, mmol/L 1.19 0.72 1.18 0.71 1.46 0.87 <0.0001
C-reactive protein, mmol/L 1.41 (0.63–3.29) 1.39 (0.61–3.20) 2.75 (1.18–5.49) <0.0001
Framingham CVD risk score 11.6 6.2 11.3 6.1 16.1 3.8 <0.0001
Type 2 diabetes, n (%) 85 (2.6) 69 (2.2) 16 (10.9) <0.0001
Data are presented as mean SD or median (interquartile range, 25th–75th percentile) and number (percentage).
aDefault estimate for BF% using the device’s unpublished BIA-BF%-equation.
CV: cardiovascular; BMI: body mass index; SBP: systolic blood pressure; HDL: high-density lipoprotein; CVD: cardiovascular disease; BF%: body fat
percentage; BIA: bioelectrical impedance analysis
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In women, these hazard ratios were 3.80 (2.85–4.99),
1.35 (1.21–1.51) and 1.52 (1.31–1.75) for the best pre-
dicting BIA-BF%-equation (Van-Loan-Mayclin), BMI
and waist circumference respectively. All in all, crude
hazard ratios for >10 BIA-BF%-equations were signiﬁ-
cantly higher than those for BMI and waist circumfer-
ence (Figure 1; Supplementary Table S5). The
prediction value of all 34 BIA-BF%-equations was
attenuated, with 33 equations remaining statistically
signiﬁcant in men and one in women after adjustment
for age and Framingham CVD risk score and creatinine
excretion. For the other obesity measures, BMI and
waist circumference were independently associated
with CVD in men. In women, BMI association with
CVD remained statistically signiﬁcant while waist
circumference was no longer related to CVD after
adjustment for Framingham CVD risk score. On
adding creatinine excretion, the predictions became
slightly stronger for both men and women (p< 0.001;
Tables 2 and 3). Formal testing for interaction between
obesity measures and gender for associations with CVD
did not yield signiﬁcant p-values.
Based on the discrimination, the C-index for the
CVD prediction was 0.700 and 0.751 in men and
women using the base model (Framingham CVD risk
score) and increased with the addition of each obesity
measure. However, the only statistically signiﬁcant
increases in C-index were found for the extended
model containing BIA (Table 4; Supplementary Table
S6). To take the comparison further, Figure 2 depicts











































































(Differences between hazard ratios)
Obesity measure Hazard ratio (95% CI)(a)
Figure 1. Comparison of the crude hazard ratios per standardized log unit increase for obesity measures in CVD prediction in
(a) men, (b) women. z-values indicate the differences between hazard ratios for BF% estimates and BMI or waist circumference. The
z-value calculation was applied as z¼ (b[O1]-b[O2])/SE, where b[O1] and b[O2] are regression coefficients of the obesity measures,
while SE is the standard error of the difference in the coefficients. This was computed as the square root of the sum of the squares of
the standard errors for two coefficients. *p<0.05; **p<0.01; ***p<0.001.
CI: confidence interval; BF%: body fat percentage; BMI: body mass index; WC: waist circumference
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the eﬀect of using the additional information from all the
obesity measures on the CVD prediction based on NRI
and IDI. The highest correct reclassiﬁcation was 30.9%
for a BIA-BF%-equation against 14.9% for BMI and
18.3% for waist circumference in men (p< 0.001). In
women, only BIA showed signiﬁcant improvements in
reclassiﬁcation, whereas BMI and waist circumference
failed to improve NRI and IDI. An overall correct
reclassiﬁcation of BIA-BF%-equation was 24.8% in
women (Figure 2; Supplementary Table S7).
Subgroup analysis by age shows that BF% and waist
circumference were independently associated with CVD
in both younger and older men while BMI discrimin-
ates cardiovascular events better in younger men
(Supplementary Figure S2).
Discussion
We identiﬁed that the association of BF% measured
by BIA was independently associated with future
cardiovascular events. The predictive value of BIA
depends on the equation used. The body fat estimates
from the best-predicting BIA-BF%-equations were
strongly associated with future cardiovascular events,
and this eﬀect was stronger when compared with BMI
and waist circumference in men and women.
Furthermore, BIA was the best method among the
obesity measures for improving cardiovascular risk
assessment of Framingham CVD risk score in men,
and the only method in women.
To the best of our knowledge, this is the ﬁrst longi-
tudinal study to compare diﬀerent BIA-BF%-
equations in the prediction of CVD. In a cross-sectional
study by Willett et al., the predictive ability of BIA was
shown to diﬀer according to the equations used, in line
with our study.13 Our study showed that the predictive
value of BIA could be improved by using a BIA-BF%-
equation ﬁtted to a speciﬁc population. For instance,
the predictive value of the body fat estimate based on
our BIA device manufacturer’s BIA-BF%-equation
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(Differences between hazard ratios)
Obesity measure Hazard ratio (95% CI)(b)
Figure 1. Continued.
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Table 2. Associations of BIA-BF%-equations, body mass index and waist circumference with cardiovascular events in men.
Obesity measures
Hazard ratio (95% CI)
Model 1 Model 2 Model 3
Body mass index 1.26 (1.12–1.42)**** 1.24 (1.10–1.40)** 1.28 (1.12–1.47)****
Waist circumference 1.30 (1.15–1.47)**** 1.27 (1.12–1.44)**** 1.32 (1.15–1.51)****
Body fat percentage
BIA 101 AKERN 1.23 (1.04–1.45)* 1.22 (1.03–1.44)* 1.23 (1.03–1.46)*
Heitmann1 1.76 (1.29–2.39)**** 1.67 (1.22–2.28)** 1.77 (1.27–2.46)***
Heitmann2 1.41 (1.17–1.70)**** 1.37 (1.13–1.65)** 1.41 (1.16–1.73)**
Segal1 1.32 (1.15–1.53)**** 1.29 (1.12–1.49)** 1.34 (1.14–1.56)***
Segal2 1.36 (1.15–1.61)**** 1.32 (1.12–1.56)** 1.35 (1.13–1.60)**
Segal3 1.68 (1.25–2.24)*** 1.59 (1.19–2.14)** 1.58 (1.18–2.13)**
Segal4 1.45 (1.19–1.76)**** 1.40 (1.15–1.71)** 1.41 (1.15–1.73)**
Segal5 1.29 (1.12–1.49)**** 1.26 (1.10–1.45)** 1.31 (1.12–1.53)**
Segal6 1.36 (1.17–1.58)**** 1.32 (1.14–1.54)**** 1.37 (1.16–1.62)****
Van-Loan-Mayclin 1.60 (1.27–2.02)**** 1.53 (1.21–1.94)**** 1.59 (1.24–2.05)****
Kyle 1.28 (1.10–1.50)*** 1.26 (1.08–1.46)** 1.28 (1.09–1.51)**
Aglago1 1.27 (1.06–1.53)* 1.24 (1.03–1.49)* 1.27 (1.04–1.54)*
Deurenberg 1.40 (1.15–1.69)**** 1.35 (1.11–1.64)** 1.37 (1.12–1.68)**
Boulier 1.22 (0.98–1.53)
Chumlea 1.26 (1.06–1.49)*** 1.23 (1.04–1.46)* 1.23 (1.03–1.47)*
Gray1 1.37 (1.17–1.60)**** 1.33 (1.14–1.55)**** 1.36 (1.16–1.61)****
Gray2 1.24 (1.06–1.45)** 1.21 (1.03–1.42)* 1.21 (1.03–1.42)*
Jebb 1.18 (1.04–1.3)* 1.16 (1.02–1.31)* 1.18 (1.03–1.35)*
Lukaski1 1.17 (1.03–1.34)* 1.15 (1.01–1.31)* 1.15 (1.01–1.32)*
Lukaski2 1.17 (1.03–1.34)* 1.15 (1.01–1.31)* 1.15 (1.01–1.32)*
Lukaski3 1.22 (1.07–1.40)** 1.20 (1.04–1.37)* 1.20 (1.05–1.38)*
Rising 1.31 (1.07–1.61)* 1.27 (1.03–1.56)* 1.29 (1.04–1.60)*
Stolarczyk 1.37 (1.18–1.59)**** 1.34 (1.15–1.55)**** 1.37 (1.18–1.61)****
Wattanapenpaiboon1 1.17 (1.03–1.33)* 1.16 (1.02–1.32)* 1.16 (1.02–1.32)*
Wattanapenpaiboon2 1.17 (1.03–1.33)* 1.15 (1.01–1.31)* 1.16 (1.01–1.32)*
Sun 1.22 (1.03–1.45)* 1.19 (1.01–1.42)* 1.19 (1.00–1.42)*
Aglago2 1.27 (1.06–1.52)* 1.24 (1.03–1.49)* 1.26 (1.04–1.53)*
Heitmann3 1.26 (1.11–1.42)**** 1.23 (1.09–1.40)** 1.25 (1.09–1.42)**
Kushner 1.18 (1.02–1.34)* 1.15 (1.00–1.32)* 1.15 (1.00–1.32)*
Kushner_Schoeller1 1.17 (1.02–1.34)* 1.15 (1.00–1.31)* 1.15 (1.00–1.32)*
Kushner_Schoeller2 1.18 (1.04–1.33)* 1.16 (1.02–1.31)* 1.17 (1.02–1.33)*
Kushner_Schoeller3 1.17 (1.04–1.33)* 1.16 (1.02–1.31)* 1.17 (1.02–1.33)*
Lukaski_Bolunchuk1 1.24 (1.04–1.47)* 1.21 (1.02–1.44)* 1.22 (1.02–1.45)*
Lukaski_Bolunchuk2 1.24 (1.04–1.49)* 1.21 (1.01–1.45)* 1.22 (1.02–1.46)*
Model1: adjusted for age; Model2: adjusted for age, Framingham CVD risk score; Model3: adjusted for age, Framingham CVD risk score, creatinine
excretion – a marker of muscle mass.





BIA: bioelectrical impedance analysis; BF%: body fat percentage; CI: confidence interval; CVD: cardiovascular disease
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Table 3. Associations of BIA-BF%-equations, body mass index and waist circumference with cardiovascular
events in women.
Obesity measures
Hazard ratio (95% CI)
Model 1 Model 2 Model 3
Body mass index 1.19 (1.04–1.37)* 1.16 (1.01–1.33)* 1.19 (1.03–1.38)*
Waist circumference 1.21 (1.02–1.43)*
Body fat percentage


































Model1: adjusted for age; Model2: adjusted for age, Framingham CVD risk score; Model3: adjusted for age, Framingham CVD
risk score, creatinine excretion – a marker of muscle mass.
Data are presented if the measures remained significant after further adjustments.
*p< 0.05
BIA: bioelectrical impedance analysis; BF%: body fat percentage; CI: confidence interval; CVD: cardiovascular disease
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was lower than at least 10 other equations. Moreover,
since the BIA devices’ default algorithms are based on
company equations and the information about these
equations is not clear, we considered it would be
better to investigate openly available algorithms as
well. In addition, according to hazard ratios and
C-indexes, the Van-Loan-Mayclin BIA-BF%-equation
was the best-predicting equation in CVD prediction in
men and women, making it worth investigating its pre-
dictive power in other populations.
Our second aim was to compare the association
between BIA and cardiovascular events with other
obesity measures, such as BMI and waist circumfer-
ence. Several studies agree with our ﬁndings, which
showed that BIA is better for CVD prediction than
BMI and waist circumference.5,14 For instance, a
long-term population-based study of 26,942 partici-
pants identiﬁed that BF% was more strongly correlated
with cardiovascular events when compared with BMI
and waist circumference.5 Marques-Vidal et al. found
that BIA-BF% permitted the capture of three times
more participants with high estimated cardiovascular
risk than BMI and almost twice as many as the waist-
to-hip ratio in 10-year CVD risk estimation.14
Nevertheless, not all the studies reported that BIA is
superior to BMI and waist circumference for estimating
CVD risk.13,15 One of the explanations for these con-
troversial results might be that they used an unsuitable
BIA-BF%-equation. Furthermore, Willett and col-
leagues’ study ﬁndings reported that fewer than 10 of
the 51 BIA-BF%-equations tested were close to but not
superior to BMI in the prediction of obesity-related
risk factors, such as fasting plasma glucose, HDL,
triglyceride and systolic blood pressure. However, com-
parison between BIA and BMI was based only on the
correlation coeﬃcients and was not supported by any
formal comparisons.13 In our prospective study, the
superiority of BIA was supported by a number of
tests, such as a z-test, C-index and NRI and IDI.
We found clear sex diﬀerences in CVD prediction
using diﬀerent obesity measures. This could be
explained by diﬀerent fat distributions in men and
women, which have diﬀerent roles in cardiovascular
risk.4,23 There is an indication that total fat expressed
in BF% and BMI were independent predictors of car-
diovascular events in both men and women, whereas
an indication of abdominal fat such as waist circum-
ference was associated with future cardiovascular
events only in men. This ﬁnding aligns with previous
studies reporting that abdominal fat distribution is
more strongly related to CVD in men. Onat et al.
identiﬁed that visceral adiposity is a better predictor
of CVD risk in men, while total fat is more closely
associated with CVD risk in women.4 Florath et al.
found an overestimation of waist circumference for
CVD risk in women but not in men.23 Furthermore,
the current CVD risk burden in men and women
argues for improvements in the risk assessment and
the prevention of CVD,24,25 especially for women.2
Our study suggests that a sex-speciﬁc CVD risk assess-
ment could be improved by using BIA as one of the
obesity measures; only BIA provided signiﬁcant
improvement in the prediction of Framingham CVD
risk scores in women.
Since our hypothesis is based on the predictive
power of body fat, we used creatinine excretion in our
Table 4. C-index for the model containing different obesity measures in prediction of cardiovascular events.
C-index (95% CI) p value C-index changes (95% CI) p value
Male
Base model 0.700 (0.678; 0.723) <0.0001 – –
Extended models – – –
BaseþBMI 0.705 (0.683; 0.728) <0.0001 0.005 (–0.002; 0.013) 0.17
BaseþWC 0.711 (0.689; 0.734) <0.0001 0.011 (–0.001; 0.023) 0.06
BaseþBF%a 0.731 (0.709; 0.753) <0.0001 0.031 (0.015; 0.047) <0.0001
Female
Base model 0.751 (0.718; 0.784) <0.0001 – –
Extended models – – –
BaseþBMI 0.759 (0.728; 0.791) <0.0001 0.009 (–0.004; 0.021) 0.18
BaseþWC 0.758 (0.725; 0.790) <0.0001 0.007 (–0.003; 0.017) 0.18
BaseþBF%a 0.774 (0.742; 0.806) <0.0001 0.023 (0.006; 0.041) 0.01
Base model: Framingham CVD risk score.
aBody fat is estimated using the Van-Loan-Mayclin BIA-BF%-equation.
CI: confidence interval; BMI: body mass index; WC: waist circumference; BF%: body fat percentage; CVD: cardiovascular disease; BIA: bioelectrical
impedance analysis
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analysis to identify whether BIA-BF% is associated
with future cardiovascular events independently of
muscle mass. A study by Srikanthan et al. showed
that a speciﬁc subgroup with high muscle mass and
lower fat mass had a lower mortality rate than other
groups.26 For our study population, a previous analysis
by Oterdoom et al. showed that muscle mass as
reﬂected by creatinine excretion predicts the develop-
ment of CVD.8 However, we found that the association
between BIA and future cardiovascular events is inde-
pendent of the creatinine excretion.
Several limitations apply to the methodology of
BIA, including the theoretical assumptions that under-
lie the technique. For example, the assumption that the
body has a uniform cylinder shape, that the body is
homogeneous and that the conductive length is directly
related to body height. Other limitations are due to
diﬀerences in membrane conductivity among various
cell types and the diﬀerences in the body’s hydration.12
These diﬀerences can vary with individual characteris-
tics such as age and sex. Therefore, BIA-equations
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Figure 2. The additive predictive value of obesity measures over the Framingham cardiovascular disease (CVD) risk score as
assessed by the paired difference of risk scores in CVD prediction. Data are shown by paired difference between the risk scores
estimated at t¼ 10 years on the probability scale using base and extended models by BMI, waist circumference and BF% (from top to
bottom) in men and women. The difference between the areas (red) under the two curves indicates the integrated discrimination
index. The difference between two black dots indicates the continuous net reclassification index. The difference between two grey
dots indicates the median improvement. y-axis, pr(Ds)¼ cumulative probability; x-axis, s¼ difference between base and extended
model risk scores.
*BF% is estimated using the Van-Loan-Mayclin BIA-BF%-equation.
BMI: body mass index; WC: waist circumference; BF%: body fat percentage; BIA: bioelectrical impedance analysis
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parameters.10,12 Regarding the crude hazard ratios,
equations in our study which incorporated age
were more strongly associated with CVD compared
with equations which did not incorporate age
(Supplementary Figure S3). It is evident that age is an
important factor in the association between body fat
and CVD. After adjustments for age, we found no dif-
ference between equations which did and those which
did not incorporate age. Furthermore, the equations
based on a female population were also the best-pre-
dicting equations in men. Taken together, our results
show that the predictive value of BIA is independent of
the formula and is generated with or without taking age
and sex into account.
The strengths of this study include the prospective
community-based cohort, the large sample size, the
long term follow-up and the extensive information on
clinical characteristics. Furthermore, this study is the
ﬁrst longitudinal evaluation which has applied various
bioelectrical impedance equations to CVD prediction.
However, our study has some limitations. We did not
perform external validation for the predictive value of
the BIA-BF%-equations. Furthermore, the number of
events recorded in women was limited.
Conclusion
The BF%s for most BIA-BF%-equations tested in men
and at least one body fat estimate in women were inde-
pendently associated with future cardiovascular events.
The predictive value of BIA depends on the equation
used to estimate body fat. The body fat estimates from
the best-predicting BIA-BF%-equations were superior
to BMI and waist circumference in how well they pre-
dicted future cardiovascular events in both men and
women. Accordingly, of the various obesity measures,
BF% is a better candidate measure for improving car-
diovascular risk assessment in women.
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